SARS-CoV / SARS-CoV-2 (COVID-19) ORF7a antibody [3C9]
GTX632602
ApplicationsImmunoFluorescence, Western Blot, ImmunoCytoChemistry
Product group Antibodies
Overview
- SupplierGeneTex
- Product NameSARS-CoV / SARS-CoV-2 (COVID-19) ORF7a antibody [3C9]
- Delivery Days Customer9
- Application Supplier NoteWB: 1:500-1:3000. *Optimal dilutions/concentrations should be determined by the researcher.Not tested in other applications.
- ApplicationsImmunoFluorescence, Western Blot, ImmunoCytoChemistry
- CertificationResearch Use Only
- ClonalityMonoclonal
- Clone ID3C9
- Concentration1 mg/ml
- ConjugateUnconjugated
- HostMouse
- IsotypeIgG1
- Storage Instruction-20°C or -80°C,2°C to 8°C
- UNSPSC12352203
References
- Hariharan VN, Shin M, Chang CW, et al. Divalent siRNAs are bioavailable in the lung and efficiently block SARS-CoV-2 infection. Proc Natl Acad Sci U S A. 2023,120(11):e2219523120. doi: 10.1073/pnas.2219523120Read this paper
- Arshad N, Laurent-Rolle M, Ahmed WS, et al. SARS-CoV-2 accessory proteins ORF7a and ORF3a use distinct mechanisms to down-regulate MHC-I surface expression. Proc Natl Acad Sci U S A. 2023,120(1):e2208525120. doi: 10.1073/pnas.2208525120Read this paper
- Hou P, Wang X, Wang H, et al. The ORF7a protein of SARS-CoV-2 initiates autophagy and limits autophagosome-lysosome fusion via degradation of SNAP29 to promote virus replication. Autophagy. 2023,19(2):551-569. doi: 10.1080/15548627.2022.2084686Read this paper
- Arshad N, Laurent-Rolle M, Ahmed WS, et al. SARS-CoV-2 accessory proteins ORF7a and ORF3a use distinct mechanisms to downregulate MHC-I surface expression. bioRxiv. 2022,:pii: 2022.05.17.492198. doi: 10.1101/2022.05.17.492198.Read this paper
- Martin-Sancho L, Lewinski MK, Pache L, et al. Functional landscape of SARS-CoV-2 cellular restriction. Mol Cell. 2021,81(12):2656-2668.e8. doi: 10.1016/j.molcel.2021.04.008Read this paper
- Ciccosanti F, Di Rienzo M, Romagnoli A, et al. Proteomic analysis identifies the RNA helicase DDX3X as a host target against SARS-CoV-2 infection. Antiviral Res. 2021,190:105064. doi: 10.1016/j.antiviral.2021.105064Read this paper
- Sauvat A, Ciccosanti F, Colavita F, et al. On-target versus off-target effects of drugs inhibiting the replication of SARS-CoV-2. Cell Death Dis. 2020,11(8):656. doi: 10.1038/s41419-020-02842-xRead this paper